Taku Naiki

56PUBLICATIONS
54CO-AUTHORS
Predictive and prognostic markersHaematological tumoursCancer therapy (excl. chemotherapy and radiation therapy)Tumour immunologyCancer diagnosis
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (56)

|Sep 02, 2026
Eosinophil Proportion May Serve as a Candidate Biomarker for Adverse Events in Patients With Urothelial Carcinoma Treated With Enfortumab Vedotin.

|Aug 28, 2026
Real-World Outcomes of Olaparib in Japanese Patients With BRCA-Mutated Metastatic Castration-Resistant Prostate Cancer: Exploratory Analysis of BRCA2 Loss and Microsatellite Instability Status.

|Jul 01, 2026
Elevation of Eosinophil Proportion After Pembrolizumab Increases the Risk of Immune-Related Adverse Events in Patients With Bladder Cancer.

|May 04, 2026
Durable Progression-Free and Treatment-Free Survival After Nivolumab Plus Ipilimumab Therapy in Metastatic Renal Cell Carcinoma: A Real-World Study with a 5-Year Minimum Follow-Up.

|Apr 29, 2026
Genetic Predictors of Progression and Skin Rash in Japanese mCSPC Patients Treated With Apalutamide: CUARTET Study.

|Mar 26, 2026
Enhanced magnetic hyperthermia using anti-PD-L1 antibody-conjugated magnetoliposomes in a murine subcutaneous bladder cancer model.

Masakazu Gonda, Noriyasu Kawai, Daiki Ishikawa

Pageof 10

Frequent Collaborators

31 joint publications

Takahiro Yasui

13 joint publications

Shuzo Hamamoto

12 joint publications

Aya Naiki-Ito

11 joint publications

Noriyasu Kawai